查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930127

全球細胞和基因治療市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Cell and Gene Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 220 Pages | 商品交期: 請詢問到貨日

價格

細胞與基因治療市場的成長因素

受生物技術、基因組學和分子生物學進步的推動，全球細胞和基因治療市場預計將在未來十年內實現顯著增長。根據 Fortune Business Insights 預測，該市場規模預計將在 2025 年達到 131.7 億美元，並在 2026 年顯著增長至 175.4 億美元，到 2034 年將達到 2005.4 億美元，預測期內複合年增長率 (CAGR) 為 35.60%。北美地區憑藉其前沿研究、完善的醫療基礎設施和強有力的監管支持，在 2025 年將以 40.10% 的市佔率引領市場。

細胞和基因療法專注於為癌症、罕見遺傳疾病和神經系統疾病等難治性疾病提供個人化治療。這些療法透過糾正或替換缺陷細胞或基因，提供長期且可能治癒的療效。產業領導者之間的合作正在加速產品開發，拜耳公司和葛蘭素史克公司等企業正大力投資研發，以拓展其治療產品線。例如，2024年9月，Evotec SE與諾和諾德公司合作，開始開發現成的細胞療法產品，體現了對創新和全球合作的重視。

市場動態

驅動因素

癌症和罕見遺傳疾病的日益普及是推動市場發展的主要因素。細胞和基因療法能夠糾正基因突變或恢復治療選擇有限的患者的細胞功能。基因組學研究和個人化醫療的進步進一步促進了標靶療法的開發。 根據世界衛生組織（2025年8月）的數據，截至2021年，全球約有774萬人患有鐮狀細胞貧血症，凸顯了創新療法的緊迫性。

抑制劑

生產流程複雜且成本高昂限制了其廣泛應用。個人化治療需要複雜的生產流程、專門的臨床試驗和嚴格的品質控制，這增加了成本並降低了可擴展性。例如，用於治療視力喪失的基因治療藥物Luxturna價格昂貴，每隻眼睛的費用約為42.5萬美元，這給患者和醫療保健系統都造成了經濟負擔。

機會

開發治療阿茲海默症、帕金森氏症和肌萎縮側索硬化症（ALS）等神經退化性疾病的新療法具有巨大的成長潛力。各公司正在利用基因編輯技術來解決疾病的根本原因。 2025年1月，拜耳公司和BlueRock Therapeutics LP啟動了VemdaneProcel的III期臨床試驗，VemdaneProcel是一種用於治療帕金森氏症的研細胞療法，這標誌著神經退化性疾病治療領域迎來了變革性的機會。

挑戰

目前，開發和生產療法所需的專業人才——科學家、臨床醫生和技術人員——嚴重短缺。根據國際細胞與基因治療學會（ISCT，2025年9月）的數據，只有35%的技術職缺人員配備充足，顯示人才短缺可能會阻礙產業發展。

市場趨勢

一個關鍵趨勢是基於CRISPR技術的精準醫療日益受到關注。 CRISPR技術能夠實現精準的基因編輯，進而提高遺傳疾病治療的療效和安全性。 2024 年 5 月，由美國國立衛生研究院 (NIH) 資助的研究人員開發出一種基於 CRISPR 技術的氨甲酰磷酸合成酶 1 (CPS1) 缺乏症療法，證明了該技術在罕見遺傳疾病領域的廣泛應用前景。

市場區隔分析

依類型

  • 在標靶癌症療法和監管審批不斷增加的推動下，細胞療法在 2026 年佔市場主導地位，市佔率高達 70.35%。例如，T 細胞受體療法 Tessela 於 2024 年 8 月獲得 FDA 批准，用於治療轉移性滑膜肉瘤。
  • 在 2024 年，基因療法佔第二大市場佔有率，其產品類型、載體類型和適應症各不相同。

依最終使用者劃分

  • 預計到 2026 年，醫院和診所將以 55.59% 的市場佔有率引領市場，因為這些專業治療需要熟練的管理，並且通常是合作開發項目的一部分。
  • 預計專科診所的複合年增長率將達到 36.99%，反映出其服務可近性和普及率的提高。

區域展望

  • 北美：在先進的研究和醫療保健基礎設施的支持下，預計該市場在 2025 年將達到 52.7 億美元，在 2026 年將達到 70 億美元。光是美國在 2026 年就佔了 65.2 億美元。
  • 歐洲：預計該市場在 2026 年將達到 61.5 億美元，其中英國、德國和法國的市場規模分別為 10 億美元、15 億美元和 7.9 億美元。
  • 亞太地區：預計2026年將達到26.7億美元，其中印度和中國的市場規模分別為2.2億美元和9.6億美元。
  • 拉丁美洲：到 2026 年將達到 11.2 億美元。
  • 中東和非洲（海灣合作委員會）：到 2025 年將達到 2.6 億美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 針對新疾病適應症的細胞和基因療法開發
  • 主要國家的監管情況
  • 市場技術進步
  • 新產品主要公司產品發布
  • 主要公司產品線分析
  • 關鍵產業趨勢：併購、業務合作、產品發布等
  • 市場格局：定價與報銷趨勢
  • 製造與供應鏈洞察
  • 市場投資與融資趨勢
  • 概述：患者獲得治療的機會與倫理考量

第五章 全球細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 細胞療法
      • 療法類型
      • 產品類型
      • 適應症
    • 基因療法
      • 產品類型
      • 載體類型
      • 適應症
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第八章 亞太地區細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
  • Vertex Pharmaceuticals Incorporated
  • Krystal Biotech, Inc.
  • Rocket Pharmaceuticals
  • CRISPR Therapeutics
  • Bayer AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd(Spark Therapeutics)
  • Bristol-Myers Squibb Company
  • Adaptimmune
Product Code: FBI114130

Growth Factors of cell and gene therapy Market

The global cell and gene therapy market is poised for exceptional growth in the coming decade, driven by advancements in biotechnology, genomics, and molecular biology. According to Fortune Business Insights, the market was valued at USD 13.17 billion in 2025, with projections indicating growth to USD 17.54 billion in 2026 and a remarkable surge to USD 200.54 billion by 2034, reflecting a CAGR of 35.60% during the forecast period. In 2025, North America dominated the market with a 40.10% share, driven by cutting-edge research, established healthcare infrastructure, and strong regulatory support.

Cell and gene therapy focuses on personalized treatments for non-drug treatable diseases, including cancers, rare genetic disorders, and neurological conditions. These therapies involve modifying or replacing defective cells and genes, offering long-term and potentially curative benefits. Collaborations among industry leaders are accelerating product development, with companies such as Bayer AG and GSK plc investing heavily in R&D to expand their pipeline of therapies. For instance, in September 2024, Evotec SE partnered with Novo Nordisk A/s to develop off-the-shelf cell therapy products, highlighting the emphasis on innovation and global collaboration.

Market Dynamics

Drivers

The rising prevalence of cancer and rare genetic disorders is a major market driver. Cell and gene therapies correct genetic mutations or restore cell function in patients with limited treatment options. Advancements in genomic research and personalized medicine further enhance the development of targeted therapies. As per the World Health Organization (August 2025), approximately 7.74 million people globally were living with sickle cell disease in 2021, emphasizing the urgent need for innovative therapies.

Restraints

High manufacturing complexities and costs limit adoption. Personalized therapies require intricate production processes, specialized clinical studies, and rigorous quality control, which increase costs and reduce scalability. For example, Luxturna, a gene therapy for vision loss, costs approximately USD 425,000 per eye, creating financial barriers for patients and healthcare systems.

Opportunities

The development of new therapies for neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS represents significant growth potential. Companies are leveraging gene editing techniques to address underlying disease causes. In January 2025, Bayer AG and BlueRock Therapeutics LP initiated the bemdaneprocel Phase III trial, an investigational cell therapy for Parkinson's disease, signaling transformative opportunities in neurodegenerative treatment.

Challenges

The market faces a shortage of skilled professionals, including scientists, clinicians, and technical staff, required to develop and manufacture therapies. As per the International Society for Cell & Gene Therapy (ISCT, September 2025), only 35% of technical positions were adequately staffed, indicating a workforce gap that may impede growth.

Market Trends

A key trend is the increasing focus on CRISPR-based precision medicine. CRISPR enables precise gene editing, improving therapy efficacy and safety for genetic disorders. In May 2024, NIH-supported researchers developed a CRISPR-based therapy for carbamoyl phosphate synthetase 1 (CPS1) deficiency, demonstrating the technology's versatility for rare genetic diseases.

Segmentation Analysis

By Type

  • Cell therapy dominated the market in 2026 with a 70.35% share, driven by targeted therapies for cancers and increased regulatory approvals. For example, Tecelra, a T-cell receptor therapy, received FDA approval in August 2024 for metastatic synovial sarcoma.
  • Gene therapy held the second-leading share in 2024, focusing on various product types, vector types, and indications.

By End User

  • Hospitals & clinics led with a 55.59% share in 2026, as these specialized therapies require skilled administration and are often part of collaborative development programs.
  • Specialty clinics are projected to grow at a CAGR of 36.99%, reflecting increased access and adoption.

Regional Outlook

  • North America: USD 5.27 billion in 2025, USD 7 billion in 2026, driven by advanced research and healthcare infrastructure; the U.S. accounted for USD 6.52 billion in 2026.
  • Europe: Expected to reach USD 6.15 billion in 2026, with the U.K., Germany, and France valued at USD 1 billion, USD 1.5 billion, and USD 0.79 billion, respectively.
  • Asia Pacific: Projected at USD 2.67 billion in 2026, with India and China at USD 0.22 billion and USD 0.96 billion.
  • Latin America: USD 1.12 billion in 2026.
  • Middle East & Africa (GCC): USD 0.26 billion in 2025.

Competitive Landscape

The market is consolidated, dominated by Novartis AG, Gilead Sciences, Inc., and Bayer AG, offering diverse CGT products and expanding globally through R&D and strategic collaborations. Other major players include Rocket Pharmaceuticals, Bristol-Myers Squibb, Krystal Biotech, Vertex Pharmaceuticals, and CRISPR Therapeutics. Key developments include FDA approvals for advanced therapies, new CAR-T cell therapies, and partnerships to strengthen onshore manufacturing.

Conclusion

The global cell and gene therapy market is projected to grow from USD 13.17 billion in 2025 to USD 200.54 billion by 2034, reflecting rapid adoption of targeted, personalized therapies for cancer, genetic, and neurodegenerative diseases. Despite challenges such as high costs and skilled workforce shortages, innovations in CRISPR-based therapies, cell engineering, and collaborative R&D are expected to drive unprecedented market expansion.

Segmentation By Type

  • Cell Therapy
    • Therapy Type
  • CAR-T Cell Therapy
  • TCR-T Cell Therapy
  • Natural Killer (NK) Cells
  • Others
    • Product Type
  • Kymriah
  • Yescarta
  • Tecartus
  • Breyanzi
  • Abecma
  • Carvykti
  • Others
    • Indication
  • Oncology
  • Others
  • Gene Therapy
    • Product Type
  • Zolgensma
  • Luxturna
  • Roctavian
  • Others
    • Vector Type
  • Viral Vectors
  • Non-Viral Vectors
    • Indication
  • Genetic Disorders
  • Ophthalmology
  • Hematology
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Others

By Geography

  • North America (By Type, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Development of Cell and Gene Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in the Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market
  • 4.10. Overview: Patient Access to the Therapy & Ethical Considerations

5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Cell Therapy
      • 5.1.1.1. Therapy Type
        • 5.1.1.1.1. CAR-T Cell Therapy
        • 5.1.1.1.2. TCR-T Cell Therapy
        • 5.1.1.1.3. Natural Killer (NK) Cells
        • 5.1.1.1.4. Others
      • 5.1.1.2. Product Type
        • 5.1.1.2.1. Kymriah
        • 5.1.1.2.2. Yescarta
        • 5.1.1.2.3. Tecartus
        • 5.1.1.2.4. Breyanzi
        • 5.1.1.2.5. Abecma
        • 5.1.1.2.6. Carvykti
        • 5.1.1.2.7. Others
      • 5.1.1.3. Indication
        • 5.1.1.3.1. Oncology
        • 5.1.1.3.2. Others
    • 5.1.2. Gene Therapy
      • 5.1.2.1. Product Type
        • 5.1.2.1.1. Zolgensma
        • 5.1.2.1.2. Luxturna
        • 5.1.2.1.3. Roctavian
        • 5.1.2.1.4. Others
      • 5.1.2.2. Vector Type
        • 5.1.2.2.1. Viral Vectors
        • 5.1.2.2.2. Non-Viral Vectors
      • 5.1.2.3. Indication
        • 5.1.2.3.1. Genetic Disorders
        • 5.1.2.3.2. Ophthalmology
        • 5.1.2.3.3. Hematology
        • 5.1.2.3.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals & Clinics
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Cell Therapy
      • 6.1.1.1. Therapy Type
        • 6.1.1.1.1. CAR-T Cell Therapy
        • 6.1.1.1.2. TCR-T Cell Therapy
        • 6.1.1.1.3. Natural Killer (NK) Cells
        • 6.1.1.1.4. Others
      • 6.1.1.2. Product Type
        • 6.1.1.2.1. Kymriah
        • 6.1.1.2.2. Yescarta
        • 6.1.1.2.3. Tecartus
        • 6.1.1.2.4. Breyanzi
        • 6.1.1.2.5. Abecma
        • 6.1.1.2.6. Carvykti
        • 6.1.1.2.7. Others
      • 6.1.1.3. Indication
        • 6.1.1.3.1. Oncology
        • 6.1.1.3.2. Others
    • 6.1.2. Gene Therapy
      • 6.1.2.1. Product Type
        • 6.1.2.1.1. Zolgensma
        • 6.1.2.1.2. Luxturna
        • 6.1.2.1.3. Roctavian
        • 6.1.2.1.4. Others
      • 6.1.2.2. Vector Type
        • 6.1.2.2.1. Viral Vectors
        • 6.1.2.2.2. Non-Viral Vectors
      • 6.1.2.3. Indication
        • 6.1.2.3.1. Genetic Disorders
        • 6.1.2.3.2. Ophthalmology
        • 6.1.2.3.3. Hematology
        • 6.1.2.3.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals & Clinics
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Cell Therapy
      • 7.1.1.1. Therapy Type
        • 7.1.1.1.1. CAR-T Cell Therapy
        • 7.1.1.1.2. TCR-T Cell Therapy
        • 7.1.1.1.3. Natural Killer (NK) Cells
        • 7.1.1.1.4. Others
      • 7.1.1.2. Product Type
        • 7.1.1.2.1. Kymriah
        • 7.1.1.2.2. Yescarta
        • 7.1.1.2.3. Tecartus
        • 7.1.1.2.4. Breyanzi
        • 7.1.1.2.5. Abecma
        • 7.1.1.2.6. Carvykti
        • 7.1.1.2.7. Others
      • 7.1.1.3. Indication
        • 7.1.1.3.1. Oncology
        • 7.1.1.3.2. Others
    • 7.1.2. Gene Therapy
      • 7.1.2.1. Product Type
        • 7.1.2.1.1. Zolgensma
        • 7.1.2.1.2. Luxturna
        • 7.1.2.1.3. Roctavian
        • 7.1.2.1.4. Others
      • 7.1.2.2. Vector Type
        • 7.1.2.2.1. Viral Vectors
        • 7.1.2.2.2. Non-Viral Vectors
      • 7.1.2.3. Indication
        • 7.1.2.3.1. Genetic Disorders
        • 7.1.2.3.2. Ophthalmology
        • 7.1.2.3.3. Hematology
        • 7.1.2.3.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals & Clinics
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Cell Therapy
      • 8.1.1.1. Therapy Type
        • 8.1.1.1.1. CAR-T Cell Therapy
        • 8.1.1.1.2. TCR-T Cell Therapy
        • 8.1.1.1.3. Natural Killer (NK) Cells
        • 8.1.1.1.4. Others
      • 8.1.1.2. Product Type
        • 8.1.1.2.1. Kymriah
        • 8.1.1.2.2. Yescarta
        • 8.1.1.2.3. Tecartus
        • 8.1.1.2.4. Breyanzi
        • 8.1.1.2.5. Abecma
        • 8.1.1.2.6. Carvykti
        • 8.1.1.2.7. Others
      • 8.1.1.3. Indication
        • 8.1.1.3.1. Oncology
        • 8.1.1.3.2. Others
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Product Type
        • 8.1.2.1.1. Zolgensma
        • 8.1.2.1.2. Luxturna
        • 8.1.2.1.3. Roctavian
        • 8.1.2.1.4. Others
      • 8.1.2.2. Vector Type
        • 8.1.2.2.1. Viral Vectors
        • 8.1.2.2.2. Non-Viral Vectors
      • 8.1.2.3. Indication
        • 8.1.2.3.1. Genetic Disorders
        • 8.1.2.3.2. Ophthalmology
        • 8.1.2.3.3. Hematology
        • 8.1.2.3.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Cell Therapy
      • 9.1.1.1. Therapy Type
        • 9.1.1.1.1. CAR-T Cell Therapy
        • 9.1.1.1.2. TCR-T Cell Therapy
        • 9.1.1.1.3. Natural Killer (NK) Cells
        • 9.1.1.1.4. Others
      • 9.1.1.2. Product Type
        • 9.1.1.2.1. Kymriah
        • 9.1.1.2.2. Yescarta
        • 9.1.1.2.3. Tecartus
        • 9.1.1.2.4. Breyanzi
        • 9.1.1.2.5. Abecma
        • 9.1.1.2.6. Carvykti
        • 9.1.1.2.7. Others
      • 9.1.1.3. Indication
        • 9.1.1.3.1. Oncology
        • 9.1.1.3.2. Others
    • 9.1.2. Gene Therapy
      • 9.1.2.1. Product Type
        • 9.1.2.1.1. Zolgensma
        • 9.1.2.1.2. Luxturna
        • 9.1.2.1.3. Roctavian
        • 9.1.2.1.4. Others
      • 9.1.2.2. Vector Type
        • 9.1.2.2.1. Viral Vectors
        • 9.1.2.2.2. Non-Viral Vectors
      • 9.1.2.3. Indication
        • 9.1.2.3.1. Genetic Disorders
        • 9.1.2.3.2. Ophthalmology
        • 9.1.2.3.3. Hematology
        • 9.1.2.3.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals & Clinics
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Cell Therapy
      • 10.1.1.1. Therapy Type
        • 10.1.1.1.1. CAR-T Cell Therapy
        • 10.1.1.1.2. TCR-T Cell Therapy
        • 10.1.1.1.3. Natural Killer (NK) Cells
        • 10.1.1.1.4. Others
      • 10.1.1.2. Product Type
        • 10.1.1.2.1. Kymriah
        • 10.1.1.2.2. Yescarta
        • 10.1.1.2.3. Tecartus
        • 10.1.1.2.4. Breyanzi
        • 10.1.1.2.5. Abecma
        • 10.1.1.2.6. Carvykti
        • 10.1.1.2.7. Others
      • 10.1.1.3. Indication
        • 10.1.1.3.1. Oncology
        • 10.1.1.3.2. Others
    • 10.1.2. Gene Therapy
      • 10.1.2.1. Product Type
        • 10.1.2.1.1. Zolgensma
        • 10.1.2.1.2. Luxturna
        • 10.1.2.1.3. Roctavian
        • 10.1.2.1.4. Others
      • 10.1.2.2. Vector Type
        • 10.1.2.2.1. Viral Vectors
        • 10.1.2.2.2. Non-Viral Vectors
      • 10.1.2.3. Indication
        • 10.1.2.3.1. Genetic Disorders
        • 10.1.2.3.2. Ophthalmology
        • 10.1.2.3.3. Hematology
        • 10.1.2.3.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Vertex Pharmaceuticals Incorporated
    • 11.2.2. Krystal Biotech, Inc.
    • 11.2.3. Rocket Pharmaceuticals
    • 11.2.4. CRISPR Therapeutics
    • 11.2.5. Bayer AG
    • 11.2.6. Novartis AG
    • 11.2.7. Gilead Sciences, Inc.
    • 11.2.8. F. Hoffmann-La Roche Ltd (Spark Therapeutics)
    • 11.2.9. Bristol-Myers Squibb Company
    • 11.2.10. Adaptimmune

List of Tables

  • Table 1: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 3: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 4: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 5: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 6: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 7: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 8: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 9: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 10: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 11: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 12: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 13: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 14: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 15: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 16: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 17: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 18: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 20: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 21: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 22: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 23: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 24: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 25: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 26: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 27: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 30: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 31: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 32: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 33: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 34: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 35: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 36: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 38: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 39: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 40: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 41: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 42: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 43: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 44: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 45: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 47: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 48: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 49: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 50: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 51: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 52: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 53: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 54: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cell and Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cell and Gene Therapy Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Cell and Gene Therapy Market Value Share (%), by End User, 2025 & 2034
  • Figure 4: Global Cell and Gene Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 5: North America Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 6: North America Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 7: North America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 8: North America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 9: North America Cell and Gene Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 10: North America Cell and Gene Therapy Market Value Share (%), By Country, 2025
  • Figure 11: Europe Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 12: Europe Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 13: Europe Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 14: Europe Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 15: Europe Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 18: Asia Pacific Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 19: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 20: Asia Pacific Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 21: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 24: Latin America Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 25: Latin America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 26: Latin America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 27: Latin America Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 30: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 31: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 32: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 33: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Cell and Gene Therapy Market Share (%), By Company, 2025